– NDA Supported by the Phase 3 PROSERA Study, Phase 2 TORREY Study and Additional Supportive Analyses –
Gossamer Bio, Inc. (NASDAQ:GOSS) (the "Company" or "Gossamer"), a clinical-stage
Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary
Gossamer Bio, Inc. (NASDAQ:GOSS) (the "Company" or "Gossamer"), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary
Gossamer Bio, Inc. (NASDAQ:GOSS) (the "Company" or "Gossamer"), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary
Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary
– $150 Million of Committed Capital: $25 Million Funded Upfront at Initial Closing, Plus an Additional $125 Million that Funds Upon FDA Acceptance of the Seralutinib NDA in PAH –
– Potential for Up to an Additional
- NDA Submission for Seralutinib in PAH On Track for September 2026 Following Receipt of Pre-NDA Type B Meeting Minutes -
- Gossamer Reacquired Worldwide Development and Commercial Rights to Seralutinib from Chiesi,
NEW YORK, Aug. 10, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Gossamer Bio, Inc. (NASDAQ:GOSS) breached their fiduciary duties to
– Pre-NDA Type B Meeting and FDA Minutes Provide Path to September 2026 NDA Submission for Seralutinib in PAH –– Gossamer Reacquires Worldwide Rights to Seralutinib, Aligning Global Commercial Control for a Potential
Gossamer Bio, Inc. (NASDAQ:GOSS) (the "Company" or "Gossamer"), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial
Gossamer Bio, Inc. (NASDAQ:GOSS) (the "Company" or "Gossamer"), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and
Gossamer Bio, Inc. (NASDAQ:GOSS) (the "Company" or "Gossamer"), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and
Gossamer Bio, Inc. (NASDAQ:GOSS) (the "Company" or "Gossamer"), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in
